Avioq, Inc.
Avioq - Model HTLV-I/II - Microelisa System
FromAvioq, Inc.
The Avioq HTLV-I/II Microelisa System is intended as a screen for donated blood and organs to prevent transmission of HTLV-I and HTLV-II to recipients of cellular blood components and as an aid in clinical diagnosis of HTLV-I or HTLV-II infection and related disease
Most popular related searches
clinical trial
antigen complex
human serum
clinical diagnosis
antigen antibody
infection disease
serum specimen
blood donation
Ease of Use
- Fast, convenient procedure: Total incubation time only 2 hours, 30 minutes
- No sample pre-dilution step
Time and Cost-Savings
- Excellent sensitivity and specificity in clinical trials providing reduced cost for confirmatory testing
- High correlation between initial and repeat duplicate results
- Direct dilution into microplate well
Confidence in Results
- Excellent performance characteristics to provide the “Right Answer Sooner”
- 99.95% specificity in random donor population seen in clinical trials (95% confidence interval of 99.89 to 99.98%)
- 100 % Sensitivity as seen in clinical trials (95% confidence interval of 99.97 to 100%)
Instrument Flexibility
- 96-well microplate with 8-well strips: Adaptable to automation and your testing volume
- 20 uL specimen volume for serum/plasma
- Consistent volumes for Wash Buffer, Conjugate, Substrate, and Stop solution